Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Comments
Loading...
BioXcel Therapeutics Analyst Ratings and Price Targets | NASDAQ:BTAI | Benzinga
BioXcel Therapeutics Inc has a consensus price target of $13.03 based on the ratings of 10 analysts. The high is $65 issued by Rodman & Renshaw on March 19, 2025. The low is $0.25 issued by B of A Securities on January 7, 2025. The 3 most-recent analyst ratings were released by Rodman & Renshaw, HC Wainwright & Co., and B of A Securities on March 19, 2025, January 30, 2025, and January 7, 2025, respectively. With an average price target of $22.75 between Rodman & Renshaw, HC Wainwright & Co., and B of A Securities, there's an implied 906.64% upside for BioXcel Therapeutics Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Rodman & Renshaw
HC Wainwright & Co.
B of A Securities
Canaccord Genuity
UBS
1calculated from analyst ratings
Analyst Ratings for BioXcel Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 03/19/2025 | Buy Now | 2776.11% | Rodman & Renshaw | Elemer Piros56% | → $65 | Initiates | → Buy | Get Alert |
| 01/30/2025 | Buy Now | 32.74% | HC Wainwright & Co. | Raghuram Selvaraju43% | $80 → $48 | Maintains | Buy | Get Alert |
| 01/07/2025 | Buy Now | -88.94% | B of A Securities | Geoff Meacham63% | $112 → $4 | Downgrade | Buy → Underperform | Get Alert |
| 01/06/2025 | Buy Now | 121.24% | Canaccord Genuity | Sumant Kulkarni43% | $112 → $80 | Maintains | Buy | Get Alert |
| 10/21/2024 | Buy Now | 121.24% | HC Wainwright & Co. | Raghuram Selvaraju43% | $112 → $80 | Maintains | Buy | Get Alert |
| 09/06/2024 | Buy Now | 209.73% | HC Wainwright & Co. | Raghuram Selvaraju43% | $112 → $112 | Reiterates | Buy → Buy | Get Alert |
| 08/30/2024 | Buy Now | 209.73% | Canaccord Genuity | Sumant Kulkarni43% | $112 → $112 | Maintains | Buy | Get Alert |
| 08/09/2024 | Buy Now | -55.75% | UBS | Colin Bristow41% | $56 → $16 | Maintains | Neutral | Get Alert |
| 08/08/2024 | Buy Now | 209.73% | HC Wainwright & Co. | Raghuram Selvaraju43% | $160 → $112 | Maintains | Buy | Get Alert |
| 06/27/2024 | Buy Now | 209.73% | Canaccord Genuity | Sumant Kulkarni43% | $112 → $112 | Maintains | Buy | Get Alert |
| 05/10/2024 | Buy Now | 342.48% | HC Wainwright & Co. | Raghuram Selvaraju43% | $160 → $160 | Reiterates | Buy → Buy | Get Alert |
| 04/23/2024 | Buy Now | 342.48% | HC Wainwright & Co. | Raghuram Selvaraju43% | → $160 | Reiterates | Buy → Buy | Get Alert |
| 03/18/2024 | Buy Now | 386.73% | HC Wainwright & Co. | Raghuram Selvaraju43% | $176 → $176 | Reiterates | Buy → Buy | Get Alert |
| 03/14/2024 | Buy Now | 209.73% | Canaccord Genuity | Sumant Kulkarni43% | $288 → $112 | Maintains | Buy | Get Alert |
| 03/13/2024 | Buy Now | 209.73% | B of A Securities | Geoff Meacham63% | $128 → $112 | Maintains | Buy | Get Alert |
| 02/21/2024 | Buy Now | 76.99% | UBS | Colin Bristow41% | $144 → $64 | Downgrade | Buy → Neutral | Get Alert |
| 11/15/2023 | Buy Now | 386.73% | HC Wainwright & Co. | Raghuram Selvaraju43% | → $176 | Reiterates | Buy → Buy | Get Alert |
| 10/31/2023 | Buy Now | 386.73% | HC Wainwright & Co. | Raghuram Selvaraju43% | → $176 | Reiterates | Buy → Buy | Get Alert |
| 10/26/2023 | Buy Now | 386.73% | HC Wainwright & Co. | Raghuram Selvaraju43% | → $176 | Reiterates | Buy → Buy | Get Alert |
| 10/05/2023 | Buy Now | — | Truist Securities | Robyn Karnauskas56% | — | Downgrade | Buy → Hold | Get Alert |
| 09/13/2023 | Buy Now | 386.73% | HC Wainwright & Co. | Raghuram Selvaraju43% | → $176 | Reiterates | Buy → Buy | Get Alert |
| 09/08/2023 | Buy Now | 386.73% | HC Wainwright & Co. | Raghuram Selvaraju43% | → $176 | Reiterates | Buy → Buy | Get Alert |
| 08/28/2023 | Buy Now | 386.73% | HC Wainwright & Co. | Raghuram Selvaraju43% | → $176 | Reiterates | Buy → Buy | Get Alert |
| 08/23/2023 | Buy Now | 76.99% | Mizuho | Graig Suvannavejh55% | → $64 | Reiterates | Neutral → Neutral | Get Alert |
| 08/18/2023 | Buy Now | 386.73% | HC Wainwright & Co. | Raghuram Selvaraju43% | $960 → $176 | Maintains | Buy | Get Alert |
| 08/15/2023 | Buy Now | 76.99% | Goldman Sachs | Corinne Jenkins46% | $192 → $64 | Maintains | Neutral | Get Alert |
| 08/15/2023 | Buy Now | 76.99% | Mizuho | Graig Suvannavejh55% | $640 → $64 | Downgrade | Buy → Neutral | Get Alert |
| 08/15/2023 | Buy Now | 1271.68% | Truist Securities | Robyn Karnauskas56% | $1136 → $496 | Maintains | Buy | Get Alert |
| 08/15/2023 | Buy Now | 784.96% | Canaccord Genuity | Sumant Kulkarni43% | $1216 → $320 | Maintains | Buy | Get Alert |
| 07/17/2023 | Buy Now | — | Guggenheim | Yatin Suneja49% | — | Downgrade | Buy → Neutral | Get Alert |
| 07/03/2023 | Buy Now | 2554.87% | HC Wainwright & Co. | Raghuram Selvaraju43% | $1056 → $960 | Maintains | Buy | Get Alert |
| 06/30/2023 | Buy Now | 1669.91% | Mizuho | Graig Suvannavejh55% | → $640 | Reiterates | Buy → Buy | Get Alert |
| 05/30/2023 | Buy Now | 2820.35% | HC Wainwright & Co. | Raghuram Selvaraju43% | → $1056 | Reiterates | Buy → Buy | Get Alert |
| 05/26/2023 | Buy Now | 1006.19% | Goldman Sachs | Corinne Jenkins46% | $448 → $400 | Maintains | Neutral | Get Alert |
| 05/17/2023 | Buy Now | 2820.35% | HC Wainwright & Co. | Raghuram Selvaraju43% | → $1056 | Reiterates | Buy → Buy | Get Alert |
| 05/11/2023 | Buy Now | 2820.35% | HC Wainwright & Co. | Raghuram Selvaraju43% | → $1056 | Reiterates | Buy → Buy | Get Alert |
| 05/10/2023 | Buy Now | 1669.91% | Mizuho | Graig Suvannavejh55% | $608 → $640 | Maintains | Buy | Get Alert |
| 05/09/2023 | Buy Now | 1935.4% | Guggenheim | Yatin Suneja49% | $800 → $736 | Maintains | Buy | Get Alert |
| 03/21/2023 | Buy Now | 2820.35% | HC Wainwright & Co. | Raghuram Selvaraju43% | $1264 → $1056 | Maintains | Buy | Get Alert |
| 03/10/2023 | Buy Now | 873.45% | Jefferies | Chris Howerton63% | $320 → $352 | Downgrade | Buy → Hold | Get Alert |
| 02/27/2023 | Buy Now | 3395.58% | HC Wainwright & Co. | Raghuram Selvaraju43% | → $1264 | Reiterates | → Buy | Get Alert |
| 02/21/2023 | Buy Now | 3395.58% | HC Wainwright & Co. | Raghuram Selvaraju43% | $1168 → $1264 | Maintains | Buy | Get Alert |
| 02/08/2023 | Buy Now | 1581.42% | Mizuho | Graig Suvannavejh55% | $384 → $608 | Maintains | Buy | Get Alert |
| 01/26/2023 | Buy Now | 1050.44% | Goldman Sachs | Corinne Jenkins46% | $256 → $416 | Maintains | Neutral | Get Alert |
| 01/03/2023 | Buy Now | 3130.09% | HC Wainwright & Co. | Raghuram Selvaraju43% | $1360 → $1168 | Maintains | Buy | Get Alert |
| 12/01/2022 | Buy Now | 607.96% | Goldman Sachs | Corinne Jenkins46% | → $256 | Upgrade | Sell → Neutral | Get Alert |
| 11/16/2022 | Buy Now | 696.46% | Mizuho | Graig Suvannavejh55% | $304 → $288 | Maintains | Buy | Get Alert |
| 11/11/2022 | Buy Now | 1006.19% | Guggenheim | Yatin Suneja49% | $448 → $400 | Maintains | Buy | Get Alert |
| 11/11/2022 | Buy Now | 3262.83% | Canaccord Genuity | Sumant Kulkarni43% | $1200 → $1216 | Maintains | Buy | Get Alert |
| 11/11/2022 | Buy Now | 696.46% | Mizuho | Graig Suvannavejh55% | $304 → $288 | Maintains | Buy | Get Alert |
| 08/24/2022 | Buy Now | 3661.06% | HC Wainwright & Co. | Raghuram Selvaraju43% | $1760 → $1360 | Maintains | Buy | Get Alert |
| 07/07/2022 | Buy Now | 740.71% | Mizuho | Graig Suvannavejh55% | → $304 | Initiates | → Buy | Get Alert |
| 05/23/2022 | Buy Now | 4767.26% | HC Wainwright & Co. | Raghuram Selvaraju43% | $2144 → $1760 | Maintains | Buy | Get Alert |
| 05/09/2022 | Buy Now | 342.48% | Goldman Sachs | Corinne Jenkins46% | $272 → $160 | Maintains | Sell | Get Alert |
| 04/14/2022 | Buy Now | 5829.2% | HC Wainwright & Co. | Raghuram Selvaraju43% | $2080 → $2144 | Maintains | Buy | Get Alert |
FAQ
What is the target price for BioXcel Therapeutics (BTAI) stock?
The latest price target for BioXcel Therapeutics (NASDAQ:BTAI) was reported by Rodman & Renshaw on March 19, 2025. The analyst firm set a price target for $65.00 expecting BTAI to rise to within 12 months (a possible 2776.11% upside). 12 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for BioXcel Therapeutics (BTAI)?
The latest analyst rating for BioXcel Therapeutics (NASDAQ:BTAI) was provided by Rodman & Renshaw, and BioXcel Therapeutics initiated their buy rating.
When was the last upgrade for BioXcel Therapeutics (BTAI)?
The last upgrade for BioXcel Therapeutics Inc happened on December 1, 2022 when Goldman Sachs raised their price target to $16. Goldman Sachs previously had a sell for BioXcel Therapeutics Inc.
When was the last downgrade for BioXcel Therapeutics (BTAI)?
The last downgrade for BioXcel Therapeutics Inc happened on January 7, 2025 when B of A Securities changed their price target from $7 to $0.25 for BioXcel Therapeutics Inc.
When is the next analyst rating going to be posted or updated for BioXcel Therapeutics (BTAI)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of BioXcel Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for BioXcel Therapeutics was filed on March 19, 2025 so you should expect the next rating to be made available sometime around March 19, 2026.
Is the Analyst Rating BioXcel Therapeutics (BTAI) correct?
While ratings are subjective and will change, the latest BioXcel Therapeutics (BTAI) rating was a initiated with a price target of $0.00 to $65.00. The current price BioXcel Therapeutics (BTAI) is trading at is $2.26, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.